Hong Kong stock market anomaly | China Biopharmaceuticals (01177.HK) rose more than 6% and announced the Phase III clinical data of the combination of pembrolizumab and anlotinib at the ASCO 2025 annual meeting.

According to the Wise Financial APP, China Biopharmaceuticals (01177.HK) rose by over 6%, as of the time of writing, it has rose by 6.03% to 4.75 Hong Kong dollars, with a turnover of 2.95 billion Hong Kong dollars.